spacer
home > ict > winter 2017 > life after brexit
PUBLICATIONS
International Clinical Trials

Life After Brexit

“It is hard to think of an industry of greater strategic importance to Britain than its pharmaceutical industry,” confirmed the UK’s Prime Minister, Theresa May (1). It is important to consider what lies ahead for pharma, particularly in clinical research, which will allow both British and global drug development to prosper after Brexit.

Following the Referendum on 23 June 2016, the UK took the historic decision to exit the EU, which will result in the British government triggering Article 50 of the Lisbon Treaty– thereby officially notifying the European Council of its intention to leave. Britain’s exit is the most significant economic demerger between major economies since the Second World War, and both parties will find themselves significantly changed by this.

Brexit has resulted in a number of uncertainties and complexities for clinical trials in the UK, but has also presented some new opportunities. It could have a considerable impact on clinical research in the following areas:
  • The EMA relocation and the Medicines Healthcare products Regulatory Agency (MHRA)
  • Clinical trial approval
  • EU regulations and clinical trial process
  • Employee talent
  • Research funding and collaboration


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Laura Brown is Managing Director of LB Training and Development, an international quality assurance and training consultancy in the pharma industry. She oversees and delivers a broad range of regulatory and management courses, as well as consulting for the pharma sector on services including project management, CTRs, standard operating procedures, the Pharma MBA and many more. Laura is also the Course Director of the MSc Regulatory Affairs at TOPRA.
spacer
Dr Laura Brown
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Winners of the 2021 CPhI Pharma Awards have now been announced

Milan, 10 November 2021: CPhI Worldwide announces the winners of the 18th edition of the CPhI Pharma Awards, hosted live in Milan, with winners spanning some 10 distinct categories. The Awards seek to recognise ‘Excellence in Pharma’ , assessing entries from the industry leading companies and individuals.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement